Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

EXTENDED ABSORPTION OF LIOTHYRONINE FROM POLY-ZINC-LIOTHYRONINE (PZL) IN HUMANS

Alexandra M. Dumitrescu, View ORCID ProfileErin C. Hanlon, Marilyn Arosemena, Olga Duchon, Matthew Ettleson, View ORCID ProfileMihai Giurcanu, View ORCID ProfileAntonio C. Bianco
doi: https://doi.org/10.1101/2021.06.14.21258437
Alexandra M. Dumitrescu
1Section of Adult and Pediatric Endocrinology and Metabolism, and Department of Public Health Sciences, University of Chicago, Chicago IL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alexd@uchicago.edu abianco@deiodinase.org
Erin C. Hanlon
1Section of Adult and Pediatric Endocrinology and Metabolism, and Department of Public Health Sciences, University of Chicago, Chicago IL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Erin C. Hanlon
Marilyn Arosemena
1Section of Adult and Pediatric Endocrinology and Metabolism, and Department of Public Health Sciences, University of Chicago, Chicago IL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olga Duchon
1Section of Adult and Pediatric Endocrinology and Metabolism, and Department of Public Health Sciences, University of Chicago, Chicago IL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Ettleson
1Section of Adult and Pediatric Endocrinology and Metabolism, and Department of Public Health Sciences, University of Chicago, Chicago IL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mihai Giurcanu
1Section of Adult and Pediatric Endocrinology and Metabolism, and Department of Public Health Sciences, University of Chicago, Chicago IL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mihai Giurcanu
Antonio C. Bianco
1Section of Adult and Pediatric Endocrinology and Metabolism, and Department of Public Health Sciences, University of Chicago, Chicago IL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Antonio C. Bianco
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Liothyronine (LT3) has been increasingly used in combination with levothyroxine (LT4) in the treatment of hypothyroidism. A metal coordinated form of LT3, known as poly-zinc-liothyronine (PZL), avoided in rats the typical T3 peak seen after oral administration of LT3.

Objectives To evaluate in healthy volunteers (i) the pharmacokinetics of PZL-derived T3 after a single dose, (ii) the pharmacodynamics of PZL-derived T3, (iii) monitoring for the adverse events; (iv) exploratory analysis of the sleep patterns after LT3, PZL or placebo administration.

Methods 12 healthy volunteers 18 to 50 years of age were recruited for a Phase 1, double-blind, randomized, single-dose placebo-controlled, cross-over study to compare PZL against LT3 or placebo. Subjects were admitted three separate times to receive a randomly assigned capsule containing placebo, 50-mcg LT3, or 50-mcg-PZL, and were observed for 48h. A 2-week washout period separated each admission.

Results LT3-derived serum T3 levels exhibited the expected profile, with a Tmax at 2h and return to basal levels by 24-36h. PZL-derived serum T3 levels exhibited a ∼30% lower Cmax that was 1 h delayed and extended into a plateau that lasted up to 6h. This was followed by a lower but much longer plateau; by 24 hours serum T3 levels still exceeded ½ of Cmax. TSH levels were similarly reduced indistinguishably in both groups.

Conclusion PZL possesses the necessary properties to achieve a much improved T3 pharma-cokinetic. Drug product development of PZL should improve the delivery of T3 even further. PZL is on track to provide hypothyroid patients with stable levels of serum T3.

Competing Interest Statement

AB is a consultant for Synhtonics, Allergan, Abbvie and BLA Technology.

Clinical Trial

This is Phase-I clinical trial; registration at ClinicalTrials.gov is not mandatory. The trial was conducted under the Food and Drug Administration (FDA) exploratory investigational new drug (IND) application (IND-137796).

Funding Statement

Funded by an SBIR grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; 5R44DK116396).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial was approved by the University of Chicago IRB and Clinical Research Center committees (IRB20-1341).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • EH ehanlon{at}bsd.uchicago.edu

  • MA Marilyn.Arosemena{at}uchospitals.edu

  • OD Olha.Duchon{at}uchospitals.edu

  • ME Matthew.Ettleson{at}uchospitals.edu

  • MG giurcanu{at}uchicago.edu

Data Availability

All relevant data are contained in the manuscript.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 15, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
EXTENDED ABSORPTION OF LIOTHYRONINE FROM POLY-ZINC-LIOTHYRONINE (PZL) IN HUMANS
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
EXTENDED ABSORPTION OF LIOTHYRONINE FROM POLY-ZINC-LIOTHYRONINE (PZL) IN HUMANS
Alexandra M. Dumitrescu, Erin C. Hanlon, Marilyn Arosemena, Olga Duchon, Matthew Ettleson, Mihai Giurcanu, Antonio C. Bianco
medRxiv 2021.06.14.21258437; doi: https://doi.org/10.1101/2021.06.14.21258437
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
EXTENDED ABSORPTION OF LIOTHYRONINE FROM POLY-ZINC-LIOTHYRONINE (PZL) IN HUMANS
Alexandra M. Dumitrescu, Erin C. Hanlon, Marilyn Arosemena, Olga Duchon, Matthew Ettleson, Mihai Giurcanu, Antonio C. Bianco
medRxiv 2021.06.14.21258437; doi: https://doi.org/10.1101/2021.06.14.21258437

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Endocrinology (including Diabetes Mellitus and Metabolic Disease)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1096)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9767)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2308)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1559)
  • Health Policy (736)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (503)
  • Infectious Diseases (except HIV/AIDS) (11641)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (237)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2142)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (517)
  • Oncology (1176)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2180)
  • Public and Global Health (4657)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (251)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)